首页> 外文OA文献 >Quality of life of metastatic urothelial cancer (mUC) patients treated with enfortumab vedotin (EV) following platinum-containing chemotherapy and a checkpoint inhibitor (CPI): Data from EV-201 cohort 1

【2h】

Quality of life of metastatic urothelial cancer (mUC) patients treated with enfortumab vedotin (EV) following platinum-containing chemotherapy and a checkpoint inhibitor (CPI): Data from EV-201 cohort 1

机译：含铂化疗和检查点抑制剂（CPI）后患有Cheftumab Vedotin（EV）治疗的转移性尿道癌（MUC）患者的生活质量：来自EV-201群组的数据

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
B.A. McGregor; P.H. O’Donnell; A. Balar; D.P. Petrylak; J.E. Rosenberg; E. Yu; D.I. Quinn; S.N. Shah; J. Pinelli; Z. Hepp; M. Galsky;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. Emerging Treatment Options for the Treatment of Metastatic Urothelial Cancer: Therapeutic Potential of Enfortumab Vedotin [J] . Rohit K Jain, William Paul Skelton IV, Jingsong Zhang Cancer Management and Research . 2020,第3期

机译：用于治疗转移性尿路上皮癌的新出现治疗方案：Enfortumab Vedotin的治疗潜力
2. Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors [J] . Julie M. Shabto, Dylan J. Martini, Yuan Liu, Cancer Medicine . 2020,第8期

机译：免疫检查点抑制剂治疗转移性尿路上皮癌患者的新风险群分层
3. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors [J] . Pier Vitale Nuzzo, Gregory R Pond, Sarah Abou Alaiwi, Journal for ImmunoTherapy of Cancer . 2020,第1期

机译：用免疫检查点抑制剂治疗转移性肾病患者的条件免疫毒性率
4. Correlations between depressive symptoms and quality of life in metastatic breast cancer patients during chemotherapy [C] . Dragomir B.I., Campean A. European Association of Psychosomatic Medicine., Annual Meeting. . 2014

机译：化疗期间转移性乳腺癌患者抑郁症状与生活质量的相关性
5. Survey to assess health-related quality of life (HRQOL) in small animal cancer patients treated with chemotherapy. [D] . Iliopoulou, Maria Andromachi. 2009

机译：评估接受化学疗法治疗的小动物癌症患者健康相关生活质量（HRQOL）的调查。
6. Current Systemic Treatment Options in Metastatic Urothelial Carcinoma after Progression on Checkpoint Inhibition Therapy—A Systemic Review Combined with Single-Group Meta-Analysis of Three Studies Testing Enfortumab Vedotin [O] . Susanne Deininger, Peter Törzsök, David Oswald, 2021

机译：转移性尿路上皮癌中的目前全身治疗方案在检查点抑制治疗后 - 一种全身审查与单群META分析的三种研究检测TESTUMAB vEdotin
7. LBA24 TROPHY-U-01 cohort 1 final results: A phase II study of sacituzumab govitecan (SG) in metastatic urothelial cancer (mUC) that has progressed after platinum (PLT) and checkpoint inhibitors (CPI) [O] . Y. Loriot, A.V. Balar, D.P. Petrylak, 2020

机译：LBA24 Trophy-U-01 Cohort 1最终结果：在铂（PLT）和检查点抑制剂（CPI）之后进行的转移性内皮癌（MUC）中的Sacituzumab Govitecan（SG）的II期研究

Quality of life of metastatic urothelial cancer (mUC) patients treated with enfortumab vedotin (EV) following platinum-containing chemotherapy and a checkpoint inhibitor (CPI): Data from EV-201 cohort 1

著录项

引文网络

相似文献

相关主题

期刊订阅